Drug failure and high development cost (est. €2.3bn/new drug) have driven enormous growth in market need for scientific tests and disease models that better translate between the laboratory and bedside.
Luxcel Biosciences Ltd (now a part of Agilent Technologies) has prototyped a platform of low cost, flexible, easy to use and accessible in vitro cell metabolism and toxicity test kits (in development) and consumable products (MitoXpress UHS® and dOxycheck™) made possible through innovative synergy of fluorescence nanosensor technology, together with advanced polymer microfabrication and electronic engineering.
H2020 SME Instrument €1m funding enables Luxcel Biosciences Ltd (now a part of Agilent Technologies) to complete the development and bring these innovative products to market.
This project has received funding from the European Union's Horizon 2020 SMEInst-2016-2017 under grant agreement No 768299 (MetaTox-HS)
For Research Use Only. Not for use in diagnostic procedures.